Shandong Weigao Group Medical Polymer FY26 interim net profit drops 23.2% to RMB 774.12 million; revenue rises 3.1% to RMB 6.85 billion

• Shandong Weigao Group Medical Polymer posted revenue of RMB 6.85 billion, up 3.1%, while net profit attributable to owners fell 23.2% to RMB 774.12 million.
• Gross profit slipped 4% to RMB 3.17 billion; gross margin narrowed 3.4 percentage points to 46.3%.
• Net exchange loss widened to RMB 91.38 million; extraordinary items were net expenses of RMB 24.94 million, including equity incentives.
• Interim dividend proposal cut to RMB 0.0854 per share; basic earnings per share declined to RMB 0.17.
• Medical device revenue rose 5.4% to RMB 3.36 billion; pharma packaging climbed 7.5% to RMB 1.25 billion, while orthopaedics fell 4.7%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Weigao Group Medical Polymer Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12297675), on August 25, 2026, and is solely responsible for the information contained therein.